MERSANA THERAPEUTICS INC's ticker is MRSN and the CUSIP is 59045L106. A total of 84 filers reported holding MERSANA THERAPEUTICS INC in Q1 2020. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $493,270 | -66.2% | 245,408 | -24.6% | 0.00% | – |
Q1 2024 | $1,458,674 | +17.4% | 325,597 | -39.2% | 0.00% | – |
Q4 2023 | $1,242,657 | +68.8% | 535,628 | -7.6% | 0.00% | – |
Q3 2023 | $736,332 | -84.9% | 579,789 | -60.8% | 0.00% | – |
Q2 2023 | $4,867,545 | +378.3% | 1,479,497 | +497.5% | 0.00% | – |
Q1 2023 | $1,017,760 | +40.8% | 247,630 | +100.7% | 0.00% | – |
Q4 2022 | $722,990 | -50.4% | 123,377 | -42.8% | 0.00% | – |
Q3 2022 | $1,458,000 | +155.8% | 215,721 | +74.8% | 0.00% | – |
Q2 2022 | $570,000 | +12.9% | 123,379 | -2.6% | 0.00% | – |
Q1 2022 | $505,000 | -33.3% | 126,703 | +4.1% | 0.00% | – |
Q4 2021 | $757,000 | -66.3% | 121,687 | -48.9% | 0.00% | – |
Q3 2021 | $2,245,000 | -56.5% | 238,034 | -37.4% | 0.00% | – |
Q2 2021 | $5,161,000 | -56.2% | 380,029 | -47.9% | 0.00% | -100.0% |
Q1 2021 | $11,794,000 | -55.0% | 728,929 | -26.0% | 0.00% | -50.0% |
Q4 2020 | $26,218,000 | +60.3% | 985,255 | +12.2% | 0.00% | 0.0% |
Q3 2020 | $16,355,000 | -34.4% | 878,329 | -17.5% | 0.00% | -33.3% |
Q2 2020 | $24,916,000 | +3419.2% | 1,064,788 | +776.9% | 0.00% | – |
Q1 2020 | $708,000 | -51.8% | 121,423 | -52.6% | 0.00% | – |
Q4 2019 | $1,469,000 | +261.8% | 256,328 | -0.3% | 0.00% | – |
Q3 2019 | $406,000 | -61.0% | 257,228 | +0.2% | 0.00% | – |
Q2 2019 | $1,040,000 | -22.9% | 256,778 | +0.2% | 0.00% | – |
Q1 2019 | $1,349,000 | +29.1% | 256,328 | 0.0% | 0.00% | – |
Q4 2018 | $1,045,000 | -59.2% | 256,328 | 0.0% | 0.00% | – |
Q3 2018 | $2,563,000 | -44.0% | 256,328 | 0.0% | 0.00% | -100.0% |
Q2 2018 | $4,578,000 | +13.2% | 256,328 | -0.1% | 0.00% | – |
Q1 2018 | $4,045,000 | -7.6% | 256,462 | -3.7% | 0.00% | -100.0% |
Q4 2017 | $4,377,000 | -85.4% | 266,406 | -84.6% | 0.00% | -75.0% |
Q3 2017 | $29,999,000 | +25.4% | 1,735,061 | 0.0% | 0.00% | +33.3% |
Q2 2017 | $23,926,000 | – | 1,735,061 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Bain Capital Life Sciences Investors, LLC | 8,663,673 | $28,503,484 | 2.94% |
Logos Global Management LP | 2,800,000 | $9,212,000 | 1.25% |
SILVERARC CAPITAL MANAGEMENT, LLC | 1,100,000 | $3,619,000 | 1.12% |
5AM Venture Management, LLC | 1,305,000 | $4,293,450 | 1.07% |
SILVERARC CAPITAL MANAGEMENT, LLC | 1,000,000 | $3,290,000 | 1.02% |
Decheng Capital Management III (Cayman), LLC | 904,268 | $2,975,042 | 0.93% |
Sarissa Capital Management LP | 2,632,900 | $8,662,241 | 0.86% |
DAFNA Capital Management LLC | 810,845 | $2,667,680 | 0.73% |
Tri Locum Partners LP | 428,307 | $1,409,130 | 0.52% |
Avidity Partners Management LP | 3,790,000 | $12,469,100 | 0.44% |